DRUG DELIVERY FROM EMBOLIC AGENTS
    1.
    发明申请
    DRUG DELIVERY FROM EMBOLIC AGENTS 审中-公开
    药物从药剂代用药

    公开(公告)号:US20110182952A1

    公开(公告)日:2011-07-28

    申请号:US13084228

    申请日:2011-04-11

    摘要: A pharmaceutical composition for embolization of blood vessels, especially for benign tumours, comprises a polymeric embolic agent and, associated with the polymer in a releasable form, a local anaesthetic agent. The polymer is preferably in particulate form, such as in the form of microspheres. A suitable polymer Is a crosslinked polyvinyl alcohol polymer formed by the copolymerization of PVA macromer with other ethylenically unsaturated monomers. The composition provides a synergistic treatment for the symptoms of tumours such as uterine fibrioids, leading to size regression as well as pain relief.

    摘要翻译: 用于栓塞血管,特别是良性肿瘤的药物组合物包含聚合物栓塞剂,并且以可释放形式的聚合物与局部麻醉剂相关联。 聚合物优选为颗粒形式,例如以微球的形式。 合适的聚合物是通过PVA大分子单体与其它烯属不饱和单体的共聚形成的交联聚乙烯醇聚合物。 该组合物对诸如子宫纤维样肿瘤的症状提供协同治疗,导致大小消退以及疼痛缓解。

    Drug delivery from stents
    2.
    发明授权
    Drug delivery from stents 有权
    药物从支架输送

    公开(公告)号:US08057814B2

    公开(公告)日:2011-11-15

    申请号:US12773674

    申请日:2010-05-04

    IPC分类号: A61F13/00

    摘要: An intravascular stent has a coat comprising a crosslinked amphiphilic polymer and a sparingly water soluble matrix metalloproteinase inhibitor (MMPI). Preferably the polymer is formed from 2-methacryloyloxy-2′-ethyltrimethylammonium phosphate inner salt, C4-18 alkyl methacrylate and reactive and/or crosslinking monomer and the MMPI is a hydroxamic acid, more preferably batimastat. Preclinical and clinical results are reported, showing good luminal areas and reduced intimal thickening.

    摘要翻译: 血管内支架具有包含交联的两亲性聚合物和微水溶性基质金属蛋白酶抑制剂(MMPI)的涂层。 优选地,聚合物由2-甲基丙烯酰氧基-2'-乙基三甲基磷酸内酯盐,甲基丙烯酸C4-18烷基酯和反应性和/或交联单体形成,MMPI是异羟肟酸,更优选巴马司他。 报道临床前和临床结果显示良好的腔面积和内膜增厚减少。

    Polymeric surface coatings
    3.
    发明授权
    Polymeric surface coatings 失效
    聚合物表面涂层

    公开(公告)号:US6087462A

    公开(公告)日:2000-07-11

    申请号:US76089

    申请日:1998-05-12

    CPC分类号: C08F246/00

    摘要: Polymers of one or more radical polymerisable monomers which polymer has pendant groups bearing a centre of permanent positive charge and other pendant groups capable of stably binding the polymer to a surface are useful in the treatment of surfaces to render them biocompatible. The polymers may contain pendant groups which bind the polymer to a surface by physisorption, covalent bonding or ionic interactions. Additionally reactive groups in the polymer may serve as points for attachment of ligands to the polymer when coated on a surface.

    摘要翻译: 聚合物具有带有永久正电荷中心的侧基的聚合物和能够将聚合物稳定地结合到表面的其它侧基的一种或多种可自由基聚合单体的聚合物可用于处理表面以使其具有生物相容性。 聚合物可以含有通过物理吸附,共价键或离子相互作用将聚合物结合到表面的侧基。 聚合物中另外的反应性基团可以用作在涂覆在表面上时将配体连接到聚合物上的点。

    Drug delivery from stents
    4.
    发明授权
    Drug delivery from stents 有权
    药物从支架输送

    公开(公告)号:US08465758B2

    公开(公告)日:2013-06-18

    申请号:US12773677

    申请日:2010-05-04

    IPC分类号: A61F13/00 A61F2/82

    摘要: A method of producing an intravascular stent has a coat comprising a crosslinked amphiphilic polymer and a sparingly water soluble matrix metalloproteinase inhibitor (MMPI). Preferably the polymer is formed from 2-methacryloyloxy-2′-ethyltrimethylammonium phosphate inner salt, C4-18 alkyl methacrylate and reactive and/or crosslinking monomer and the MMPI is a hydroxamic acid, more preferably batimastat. Preclinical and clinical results are reported, showing good luminal areas and reduced intimal thickening.

    摘要翻译: 生产血管内支架的方法具有包含交联的两亲聚合物和微水溶性基质金属蛋白酶抑制剂(MMPI)的涂层。 优选地,聚合物由2-甲基丙烯酰氧基-2'-乙基三甲基磷酸内酯盐,甲基丙烯酸C4-18烷基酯和反应性和/或交联单体形成,MMPI是异羟肟酸,更优选巴马司他。 报道临床前和临床结果显示良好的腔面积和内膜增厚减少。

    Phosphoric acid esters and their use in the preparation of biocompatible
surfaces
    5.
    发明授权
    Phosphoric acid esters and their use in the preparation of biocompatible surfaces 失效
    磷酸酯及其在制备生物相容性表面中的应用

    公开(公告)号:US5599587A

    公开(公告)日:1997-02-04

    申请号:US50167

    申请日:1993-04-30

    摘要: A process for the preparation of compounds of formula (I) in which Z is hydrogen or --NHZ is an activated amine group capable of reacting with a surface, the groups R are the same or different and each is a straight or branched C.sub.1 -C.sub.4 alkyl group, preferably methyl, n is from 2 to 6, and X is a straight or branched C.sub.1-20 alkylene group, or X is a group of formula --(CH.sub.2 CH.sub.2 O).sub.b --, or --(CH.sub.2).sub.c --Ar--(CH.sub.2).sub.d -- where b is from 1 to 20, c and d are the same or different and each is from 0 to 5, and Ar is a para- or meta- disubstituted phenyl group (preferably a para-disubstituted phenyl group) which is optionally further substituted by one or more C.sub.1 -C.sub.4 alkyl groups, or an acid addition salt thereof or a hydrate thereof, new compounds of formula (I) and salts and hydrates thereof and the use of compounds of formula (I) and salts and hydrates thereof in treating surfaces to render them more biocompatible.

    摘要翻译: PCT No.PCT / GB91 / 01934 Sec。 371日期:1993年04月30日 102(e)日期1993年4月30日PCT 1991年11月5日PCT PCT。 出版物WO92 / 07858 日期1992年5月14日制备其中Z为氢或-NHZ为与表面反应的活化胺基的式(I)化合物的方法,基团R相同或不同,各自为直链或 支链C 1 -C 4烷基,优选甲基,n为2至6,X为直链或支链C 1-20亚烷基,或X为式 - (CH 2 CH 2 O)b - 或 - (CH 2)c -Ar-(CH2)d-,其中b为1至20,c和d相同或不同,各自为0至5,并且Ar为对 - 或间 - 二取代的苯基(优选为对二取代的 苯基),其任选进一步被一个或多个C 1 -C 4烷基取代,或其酸加成盐或其水合物,新的式(I)化合物及其盐和水合物以及式(I )及其盐和水合物在处理表面以使它们更具生物相容性。

    Polymeric surface coatings
    6.
    发明授权
    Polymeric surface coatings 失效
    聚合物表面涂层

    公开(公告)号:US06284854B1

    公开(公告)日:2001-09-04

    申请号:US09074407

    申请日:1998-05-08

    IPC分类号: C08F22034

    摘要: A non-crosslinked biocompatible polymer is formed from a radical polymerisable ethylenically unsaturated zwitterionic monomer containing a sulpho-betaine zwitterionic group and a radical polymerisable ethylenically unsaturated comonomer containing a hydrophobic group selected from C6-24-alkyl, C1-24-fluoroalkyl and siloxane groups. Suitable copolymers are of N,N-dimethyl ammonium-N-propylsulphonate-N-ethyl methacrylate and dodecylmethacrylate. The polymer may be used to coat substrates to render them biocompatible, especially hemocompatible. The hydrophobic groups render the polymer particularly suitable for coating hydrophobic substrates.

    摘要翻译: 非交联生物相容性聚合物由含有磺基甜菜碱两性离子基团的可自由基聚合的烯属不饱和两性离子单体和含有选自C 6-24烷基,C 1-14-氟烷基和硅氧烷基团的疏水基团的可自由基聚合的烯属不饱和共聚单体形成 。 合适的共聚物是N,N-二甲基-N-丙基磺酸铵-N-甲基丙烯酸乙酯和十二烷基甲基丙烯酸酯。 聚合物可以用于涂覆底物以使其生物相容,特别是血液相容性。 疏水基团使聚合物特别适用于涂覆疏水性底物。

    DRUG DELIVERY FROM STENTS
    9.
    发明申请
    DRUG DELIVERY FROM STENTS 有权
    药物从STENTS递送

    公开(公告)号:US20100275431A1

    公开(公告)日:2010-11-04

    申请号:US12773677

    申请日:2010-05-04

    IPC分类号: A61L27/54 B23P25/00

    摘要: A method of producing an intravascular stent has a coat comprising a crosslinked amphiphilic polymer and a sparingly water soluble matrix metalloproteinase inhibitor (MMPI). Preferably the polymer is formed from 2-methacryloyloxy-2′-ethyltrimethylammonium phosphate inner salt, C4-18 alkyl methacrylate and reactive and/or crosslinking monomer and the MMPI is a hydroxamic acid, more preferably batimastat. Preclinical and clinical results are reported, showing good luminal areas and reduced intimal thickening.

    摘要翻译: 生产血管内支架的方法具有包含交联的两亲聚合物和微水溶性基质金属蛋白酶抑制剂(MMPI)的涂层。 优选地,聚合物由2-甲基丙烯酰氧基-2'-乙基三甲基磷酸内酯盐,甲基丙烯酸C4-18烷基酯和反应性和/或交联单体形成,MMPI是异羟肟酸,更优选巴马司他。 报道临床前和临床结果显示良好的腔面积和内膜增厚减少。

    DRUG DELIVERY FROM STENTS
    10.
    发明申请
    DRUG DELIVERY FROM STENTS 有权
    药物从STENTS递送

    公开(公告)号:US20100222867A1

    公开(公告)日:2010-09-02

    申请号:US12773674

    申请日:2010-05-04

    IPC分类号: A61F2/06

    摘要: An intravascular stent has a coat comprising a crosslinked amphiphilic polymer and a sparingly water soluble matrix metalloproteinase inhibitor (MMPI). Preferably the polymer is formed from 2-methacryloyloxy-2′-ethyltrimethylammonium phosphate inner salt, C4-18 alkyl methacrylate and reactive and/or crosslinking monomer and the MMPI is a hydroxamic acid, more preferably batimastat. Preclinical and clinical results are reported, showing good luminal areas and reduced intimal thickening.

    摘要翻译: 血管内支架具有包含交联的两亲性聚合物和微水溶性基质金属蛋白酶抑制剂(MMPI)的涂层。 优选地,聚合物由2-甲基丙烯酰氧基-2'-乙基三甲基磷酸内酯盐,甲基丙烯酸C4-18烷基酯和反应性和/或交联单体形成,MMPI是异羟肟酸,更优选巴马司他。 报道临床前和临床结果显示良好的腔面积和内膜增厚减少。